CVC and Temasek to buy $2 billion generic drugs firm Alvogen: Reuters

European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, Reuters News reported.

ByReuters News

22 June 2015•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals North America US Briefs

CVC and Temasek to buy $2 billion generic drugs firm Alvogen: Reuters

Temasek

Goldman Sachs

Jefferies

Thomson Reuters

Related articles